Fetoplacental failure in cervical disease
Atabieva D.A., Chilova R.A., Gadaeva I.V., Kovalyov M.I., Pikuza T.V., Odnokopytnyi A.V.
Архив акушерства и гинекологии им. В.Ф. Снегирева
Т. 2, № 1, С. 30-34
Опубликовано: 15 2015
Тип ресурса: Статья
Аннотация:
Fetoplacental failure in patients with inflammatory diseases of the cervix uteri was studied. The study was carried out in 112 pregnant women, forming 2 groups: with (n = 74) and without cervical disease (n = 38). The patients’ ages varied from 22 to 42 years (29.1 ± 2.14 years). The study was carried out by instrumental, cytological, and bacteriological methods. Antiinflammatory therapy and correction of local immunity promoted elimination of bacterial agents and reduction of inflammatory changes in the cervix uteri. Fetoplacental failure was treated by vasodilatants and drugs normalizing the microcirculation in the placenta and uterus.
Язык текста: Русский
ISSN: 2313-8726
Atabieva D.A.
Chilova R.A. Raisa A.
Gadaeva I.V.
Kovalyov M.I.
Pikuza T.V.
Odnokopytnyi A.V.
Первый МГМУ им. И.М. Сеченова МЗ РФ
I.M. Sechenov First Moscow State Medical University
V.F. Snegirev Clinic of Obstetrics and Gynecology
Fetoplacental failure in cervical disease
Текст визуальный электронный
Архив акушерства и гинекологии им. В.Ф. Снегирева
Eco-Vector
Т. 2, № 1 С. 30-34
2015
фетоплацентарная недостаточность
fetoplacental failure
воспалительная патология шейки матки у беременных
cervical inflammation in pregnancy
Статья
Fetoplacental failure in patients with inflammatory diseases of the cervix uteri was studied. The study was carried out in 112 pregnant women, forming 2 groups: with (n = 74) and without cervical disease (n = 38). The patients’ ages varied from 22 to 42 years (29.1 ± 2.14 years). The study was carried out by instrumental, cytological, and bacteriological methods. Antiinflammatory therapy and correction of local immunity promoted elimination of bacterial agents and reduction of inflammatory changes in the cervix uteri. Fetoplacental failure was treated by vasodilatants and drugs normalizing the microcirculation in the placenta and uterus.